Form 4: Inhibrx Biosciences Director Jon Faiz Kayyem Granted 15,000 Stock Options

Inhibrx Biosciences, Inc. Director Jon Faiz Kayyem was granted 15,000 stock options with an exercise price of $12.91 per share, exercisable from May 28, 2026.

Summary

• Jon Faiz Kayyem, a Director of Inhibrx Biosciences, Inc. (INBX), acquired 15,000 derivative securities in the form of stock options.
• The transaction date for this acquisition was May 28, 2025.
• Each stock option has an exercise price of $12.91.
• The options will become fully exercisable on May 28, 2026, contingent upon Mr. Kayyem's continued service to the company.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Mr. Kayyem beneficially owns 15,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the grant of stock options aligns the director's interests with shareholders and incentivizes continued service, which is generally viewed favorably.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options' value increases with the company's stock price.
• The vesting schedule, tied to continued service, incentivizes long-term commitment from the director.

Future Outlook

The stock options granted to Director Jon Faiz Kayyem are structured to incentivize his continued service to Inhibrx Biosciences, Inc. through at least May 28, 2026, aligning his future compensation with the company's stock performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to attract and retain talent while aligning their financial interests with long-term shareholder value creation.

Related Party Transactions

• The grant of stock options to a director is a related party transaction, representing compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The stock options will become fully exercisable on May 28, 2026, provided the reporting person continues their service.

Key Dates

Keywords

Inhibrx Biosciences, INBX, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership